Consistent with the lipolytic effect of IL-6, inhibition of IL-6R using tocilizumab in RA patients leads frequently to weight gain and dyslipidemia by increasing the levels of cholesterol and triglycerides and therefore potentially increasing CVR [38,39]. Here, IL6R is linked to metabolic syndrome.